Abstract 153P
Background
The approval of several PD-1/L1 axis inhibitors has revolutionized cancer therapy and established a role for CD8+ T cells in tumor destruction. While anti-PD-1 therapy has demonstrated durable responses, only a subset of patients respond. To improve response rates, we developed a multispecific PD-1/CD73 targeting DFC. CD73 catalyzes the rate limiting step in production of immuno-suppressive adenosine, which inhibits immune cell activation through a mechanism distinct from PD-1. Herein, we describe a first-in-class dual targeting DFC, comprising a multivalent conjugate of a small molecule CD73 inhibitor to a proprietary human IgG1 Fc-fusion with a PD-1 inhibitor peptide. This dual-targeting DFC has potential for differentiation from approved PD-1/L1 inhibitors.
Methods
Binding of the dual targeting DFC to biotinylated hPD-1 was determined using a commercial kit and to human CD8+ T cells by flow cytometry. CD73 inhibition was determined in cell-free and cell-based assays. Efficacy was evaluated in transgenic mice expressing human PD-1/PD-L1 with MC-38 (hPD-L1) tumors (Genoway, France). Tumor volumes were recorded and statistical analysis was by t-test (Mann-Whitney) or two-way ANOVA.
Results
The dual targeting DFC demonstrated potent activity against both checkpoint targets: Binding to hPD-1 with an IC50 of < 1 nM and functional inhibition of CD73 with an EC50 of 9 nM. Efficacy was determined in a humanized mouse model against the colon cell line MC-38 (hPD-L1). The dual targeting DFC demonstrated a statistically significant reduction in tumor volume (∼55%) at a dose of 3 mg/kg (P<0.0001). Pembrolizumab biosimilar at 10 mg/kg did not result in a significant reduction in tumor volume.
Conclusions
This work describes a dual targeting DFC with potent activity against two validated immune checkpoint pathways. The in vitro activity translated to efficacy in a humanized mouse model at doses as low as 3 mg/kg. The relative contributions of each ligand to activity against different tumors is under investigation as Cidara’s first multispecific DFC advances through preclinical development.
Legal entity responsible for the study
Cidara Therapeutics.
Funding
Cidara Therapeutics.
Disclosure
J. Levin, S. Döhrmann, N. Dedeic, A. Almaguer, D. Zuill, E. Abelovski, J. Fortier, Q. Zhao, M. Hernandez, K. Amundson, M. Moniz, H. Chen, D. Panickar, T. Lam, T. Brady, A. Borchardt, J.N. Cole, G. Hough, J.B. Locke, L.W. Tari: Financial Interests, Personal, Full or part-time Employment: Cidara Therapeutics.
Resources from the same session
46P - Immunoprofiling of Peripheral Blood Cells as a Potential Predictor of Immune-Related Toxicity of PD-1 Inhibitors
Presenter: Jan Podhorec
Session: Poster Display
47TiP - A real-world study of multiparametric prediction of the efficacy of immune checkpoint inhibitors in combination with chemotherapy for advanced non-small cell lung cancer
Presenter: Zihan Zhou
Session: Poster Display
51P - Phase 1B (Ph1b), MESOVAX clinical trial of pembrolizumab (P) and dendritic cell vaccine (DCvax) in advanced pleural and peritoneal mesothelioma (M): preliminary results
Presenter: Laura Ridolfi
Session: Poster Display
52P - The dependence of TKI-resistant lung cancer cells on EGFR increases sensitivity to EGFR-CAR NK.
Presenter: Sumei Chen
Session: Poster Display
53P - Integrin-_v_6 targeted CAR T-cells in an immunocompetent orthotopic model of pancreatic cancer
Presenter: Nicholas Brown
Session: Poster Display
55P - DPP9 promotes renal cancer PD-L1 expression through SHMT2-BRISC complex
Presenter: wei zhang
Session: Poster Display
56P - FOXM1D in T cells promotes the transcription of PD-1 by interacting with HCFC1 and regulating the killing of renal cancer cells
Presenter: yue wang
Session: Poster Display
57P - Anatomical location of metastasis and composition of the final infusion product in metastatic melanoma (MM) patients treated with tumor-infiltrating lymphocytes (TIL)
Presenter: Joachim Stoltenborg Granhøj
Session: Poster Display
58P - Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers
Presenter: Liangping Li
Session: Poster Display
59P - Revolutionizing cell therapy testing by co-culturing 3D patient derived cancer models and circulating immune cells on Organ-on-chip platform
Presenter: silvia Scaglione
Session: Poster Display